Hepatobiliary transporters and drug-induced cholestasis
- PMID: 17006912
- DOI: 10.1002/hep.21359
Hepatobiliary transporters and drug-induced cholestasis
Abstract
Drug-induced liver injury is an important clinical problem with significant morbidity and mortality. Whereas for most hepatocellular forms of drug-induced hepatic injury the underlying pathophysiological mechanism is poorly understood, there is increasing evidence that cholestatic forms of drug-induced liver damage result from a drug- or metabolite-mediated inhibition of hepatobiliary transporter systems. In addition to their key role in determining hepatic drug exposure and clearance, the coordinated action of these transport systems is essential for bile formation and the biliary secretion of cholephilic compounds and xenobiotics. Any drug-mediated functional disturbance of these processes can lead to an intracellular accumulation of potentially harmful bile constituents and result in the development of cholestatic liver cell damage. In addition to direct drug-mediated inhibition of hepatocellular transport, function of these transporters can be altered by pre-existing hepatic disease and genetic factors, which contribute to the development of drug-induced cholestasis in susceptible individuals. This review summarizes current knowledge about the function of hepatobiliary uptake and efflux systems and discusses factors that might predispose to drug-induced cholestasis.
Similar articles
-
Mechanisms of hepatic transport of drugs: implications for cholestatic drug reactions.Semin Liver Dis. 2002;22(2):123-36. doi: 10.1055/s-2002-30099. Semin Liver Dis. 2002. PMID: 12016544 Review.
-
Cholestasis: pathophysiology and pathobiochemistry.Z Gastroenterol. 1993 Feb;31 Suppl 2:11-5. Z Gastroenterol. 1993. PMID: 7483688 Review.
-
Temporal relationship of changes in hepatobiliary function and morphology in rats following alpha-naphthylisothiocyanate (ANIT) administration.Toxicol Appl Pharmacol. 1993 Mar;119(1):108-14. doi: 10.1006/taap.1993.1049. Toxicol Appl Pharmacol. 1993. PMID: 8470113
-
Pharmacogenetics of hepatocellular transporters.Pharmacogenetics. 2003 Apr;13(4):189-98. doi: 10.1097/00008571-200304000-00003. Pharmacogenetics. 2003. PMID: 12668915 Review.
-
Hepatobiliary transport: molecular mechanisms of development and cholestasis.Pediatr Res. 1998 Aug;44(2):141-7. doi: 10.1203/00006450-199808000-00001. Pediatr Res. 1998. PMID: 9702905 Review.
Cited by
-
Simple and rapid quantitation of 21 bile acids in rat serum and liver by UPLC-MS-MS: effect of high fat diet on glycine conjugates of rat bile acids.Nagoya J Med Sci. 2013 Feb;75(1-2):57-71. Nagoya J Med Sci. 2013. PMID: 23544269 Free PMC article.
-
Role of Cytochrome P450 Enzymes in the Metabolic Activation of Tyrosine Kinase Inhibitors.Int J Mol Sci. 2018 Aug 11;19(8):2367. doi: 10.3390/ijms19082367. Int J Mol Sci. 2018. PMID: 30103502 Free PMC article. Review.
-
Validation of Pharmacological Protocols for Targeted Inhibition of Canalicular MRP2 Activity in Hepatocytes Using [99mTc]mebrofenin Imaging in Rats.Pharmaceutics. 2020 May 27;12(6):486. doi: 10.3390/pharmaceutics12060486. Pharmaceutics. 2020. PMID: 32471244 Free PMC article.
-
Mechanisms of drug-induced liver injury: from bedside to bench.Nat Rev Gastroenterol Hepatol. 2011 Apr;8(4):202-11. doi: 10.1038/nrgastro.2011.22. Epub 2011 Mar 8. Nat Rev Gastroenterol Hepatol. 2011. PMID: 21386809 Review.
-
Primary Human Hepatocyte Spheroids as Tools to Study the Hepatotoxic Potential of Non-Pharmaceutical Chemicals.Int J Mol Sci. 2021 Oct 12;22(20):11005. doi: 10.3390/ijms222011005. Int J Mol Sci. 2021. PMID: 34681664 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources